International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	THE ROLE OF ARTIFICIAL INTELLIGENCE IN EARLY DETECTION OF HEART DISEASES: SOCIAL IMPLICATIONS AND ETHICAL CHALLENGES
DOI	https://doi.org/10.31435/ijitss.1(49).2026.4733
RECEIVED	08 December 2025
ACCEPTED	25 January 2026
PUBLISHED	09 February 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

THE ROLE OF ARTIFICIAL INTELLIGENCE IN EARLY DETECTION OF HEART DISEASES: SOCIAL IMPLICATIONS AND ETHICAL CHALLENGES

Paweł Słoma *(Corresponding Author, Email: pawelsloma10@gmail.com)*
Ludwik Rydygier Memorial Specialized Hospital, Cracow, Poland
ORCID ID: 0000-0002-9856-0553

Paulina Dybiak
Ludwik Rydygier Memorial Specialized Hospital, Cracow, Poland
ORCID ID: 0009-0002-4825-183X

Adrian Morawiec
Ludwik Rydygier Memorial Specialized Hospital, Cracow, Poland
ORCID ID: 0000-0001-7083-7656

Maciej Zachara
Fryderyk Chopin University Hospital, Rzeszow, Poland
ORCID ID: 0009-0008-9994-9182

Mateusz Bartoszek
Fryderyk Chopin University Hospital, Rzeszow, Poland
ORCID ID: 0000-0003-4354-2566

Patryk Harnicki
Fryderyk Chopin University Hospital, Rzeszow, Poland
ORCID ID: 0009-0008-2689-6366

Mikołaj Grodzki
Fryderyk Chopin University Hospital, Rzeszow, Poland
ORCID ID: 0009-0003-3368-3119

Jakub Minas
Regional Specialized Hospital No. 4, Bytom, Poland
ORCID ID: 0009-0008-6190-5942

Erwin Grzegorzak
CM Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0004-8720-0503

Rafał Pelczar
CM Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0000-0002-9510-6056

Oliwia Krawczyk
LUX MED Sp. z o.o., Cracow, Poland
ORCID ID: 0009-0005-7578-0202

ABSTRACT

The dynamic development of modern technologies, particularly artificial intelligence (AI), is significantly impacting the functioning of modern healthcare systems, opening up new opportunities for the early detection of cardiovascular diseases, which remain one of the leading causes of death worldwide. Lifestyle changes associated with technological advancements are contributing to the rise in the incidence of lifestyle diseases, significantly increasing the risk of developing cardiovascular disease. In this context, early diagnosis and effective prevention are becoming key public health priorities.

The aim of this paper is to analyze the role of AI in the early detection of heart disease, taking into account its medical, social, and ethical aspects. Methods based on machine and deep learning enable the analysis of large and complex medical datasets, such as electrocardiograms, imaging studies, electronic medical records, and data from wearable devices. The use of AI allows for the identification of subtle pathological changes that often appear before the onset of clinical symptoms, supporting the transition from reactive to preventive and personalized medicine.

At the same time, the implementation of AI systems for cardiology screening has significant social implications. While these technologies can increase the availability of early diagnosis and improve the utilization of healthcare resources, there is a risk of exacerbating health inequalities resulting from algorithmic biases, limited data representativeness, and the digital divide. Furthermore, ethical challenges arise related to the protection of sensitive data, the transparency and explainability of algorithms, and accountability for clinical decisions.

The paper emphasizes that artificial intelligence should serve as a tool supporting clinical decisions, while maintaining the physician's central role in the diagnostic and therapeutic process. Responsible integration of AI requires building trust, transparent communication with patients, and the creation of a coherent regulatory framework. The societal value of artificial intelligence in cardiology depends on its ethical, equitable, and human-centered implementation.

KEYWORDS

Artificial Intelligence, Early Detection, Heart Diseases Preventions, Ethics, Social Impact, Healthcare Technology, Medical Ethics

CITATION

Paweł Słoma, Paulina Dybiak, Adrian Morawiec, Maciej Zachara, Mateusz Bartoszek, Patryk Harnicki, Mikołaj Grodzki, Jakub Minas, Erwin Grzegorzak, Rafał Pelczar, Oliwia Krawczyk. (2026) The Role of Artificial Intelligence in Early Detection of Heart Diseases: Social Implications and Ethical Challenges. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2025.4733

1. Introductions:

With the development of civilization and the dynamic advancement of modern technologies, people are gaining an increasing number of tools designed to facilitate daily functioning and improve the overall quality of life. Technological progress impacts almost every area of human activity, including communication, work, education, and healthcare. Process automation, the digitization of services, and the implementation of advanced IT systems contribute to increased efficiency, convenience, and security. At the same time, however, civilizational development brings with it a number of challenges and threats, which are increasingly perceived as unintended consequences of technological progress.

One of the most significant problems facing modern societies is the growing incidence of so-called lifestyle diseases. Profound changes in lifestyle, working conditions, and leisure activities have led to a significant portion of the population leading a sedentary lifestyle characterized by insufficient physical activity. Office work, prolonged use of electronic devices, limited daily exercise, and the replacement of human labor with machines and automated systems have contributed to the increased incidence of obesity, type 2 diabetes, hypertension, and lipid disorders. These conditions are closely linked to the development of cardiovascular disease, which constitutes one of the greatest health burdens in modern medicine.

Cardiovascular disease, including ischemic heart disease, myocardial infarction, stroke, and heart failure, remains the leading cause of death both in Poland and globally. According to data from the Central Statistical Office (GUS), cardiovascular disease is the most common cause of death in Poland, accounting for approximately 37% of all registered deaths. Despite a decline in mortality from these diseases compared to the 1990s, when they accounted for over 50% of all deaths, they remain a serious challenge for public health and the healthcare system.

A particularly important indicator illustrating the scale of the problem is the standardized mortality rate. In 2023, it was 297 deaths per 100,000 population. Despite long-term improvements, this rate remains high and reflects the persistent health risks associated with cardiovascular disease. An aging population, persistent risk factors—both modifiable and non-modifiable—and inequalities in access to preventive care and specialized medical care contribute to the continued prevalence of these conditions. Consequently, effective prevention and early diagnosis are increasingly recognized as key health policy priorities.[1]

In this context, the dynamic development of modern medical technologies, particularly artificial intelligence (AI) and machine learning methods, is gaining increasing importance. These technologies offer new opportunities for analyzing large medical data sets, identifying complex disease patterns, and predicting the risk of cardiovascular disease at an early, often asymptomatic stage. AI algorithms are increasingly used in the analysis of electrocardiographic recordings, imaging studies, electronic medical records, and data from wearable devices.

Early detection of cardiovascular disease plays a key role in improving treatment effectiveness and patient prognosis. The use of AI enables not only faster and more precise diagnosis but also the personalization of therapeutic strategies and the implementation of preventive measures tailored to the patient's individual risk profile. Early identification of high-risk individuals can lead to timely lifestyle modifications, the implementation of pharmacological treatment, and more intensive clinical monitoring, which can ultimately contribute to reducing morbidity and mortality.

At the same time, the increasing integration of artificial intelligence into clinical practice raises significant social and ethical challenges. Issues related to the protection of sensitive medical data, the transparency of algorithms, potential biases in decision-making systems, and the division of responsibility between medical personnel and technological tools require special attention. Furthermore, the increasing role of AI may impact the traditional doctor-patient relationship, altering patterns of trust, communication, and shared decision-making.

Therefore, analyzing the role of artificial intelligence in the early detection of cardiovascular disease should go beyond purely technological and medical aspects. It is essential to adopt a broader social and ethical perspective, considering the impact of these innovations on patients, healthcare professionals, and society as a whole. Such a holistic approach allows for a more comprehensive understanding of both the potential and limitations of using artificial intelligence to address one of the most serious health challenges facing the world today.

2. Definitions and Pathophysiology of Cardiovascular Diseases

Circulatory system diseases (CVDs) encompass a group of heart diseases and organizations that are among the most serious developments worldwide. According to accepted clinical definitions, circulatory system diseases include major cardiovascular diseases, heart failure, arrhythmias, extrinsic cardiovascular diseases, cerebrovascular diseases, and peripheral vascular diseases. There may be differences in the clinical presentation and course of the disease, shared pathophysiological mechanisms, and overlapping risk factors.

From a vascular perspective, they exist as a pathological condition resulting from other structural or functional changes in the heart or vascular system that impair blood flow and perfusion control. The development of CVD is multifactorial and involves the interaction of specific demands, environmental influences, biological factors, lifestyle, and biological aging processes [2,7].

2.1 Pathophysiological Mechanisms

The pathophysiology of cardiovascular disease is characterized by gradual and often asymptomatic progression, making early detection particularly challenging. One of the main mechanisms underlying many cardiovascular diseases is atherosclerosis – a chronic inflammatory process that attacks the arterial wall. Atherosclerosis begins with endothelial dysfunction, followed by lipid accumulation, inflammatory cell infiltration, plaque formation, and ultimately arterial narrowing or plaque rupture. This process plays a key role in the development of coronary artery disease, myocardial infarction, and ischemic stroke [2,8].

Endothelial dysfunction is an early and critical stage in cardiovascular pathophysiology. It is characterized by impaired vasodilation, increased oxidative stress, and enhanced proinflammatory signaling in the vascular endothelium. Major cardiovascular risk factors, such as hypertension, smoking, diabetes, dyslipidemia, and a sedentary lifestyle, contribute to endothelial damage and accelerate disease progression. Importantly, endothelial dysfunction can precede overt clinical disease by many years, highlighting the importance of early detection strategies.

Heart failure is another important category of cardiovascular disease and is defined as a clinical syndrome resulting from structural or functional impairment of ventricular filling or blood ejection. Key pathophysiological mechanisms include myocardial ischemia, pressure or volume overload, cardiomyocyte loss, neurohormonal activation, and maladaptive cardiac remodeling. These processes lead to progressive deterioration of cardiac function and are often accompanied by subtle electrical and mechanical changes that can be detectable before the onset of clinical symptoms [3,5].

Cardiac arrhythmias, including atrial fibrillation, result from disturbances in the electrical conduction system of the heart. Structural remodeling, fibrosis, inflammation, and autonomic nervous system imbalances contribute to abnormal impulse generation and propagation. Atrial fibrillation, in particular, is often asymptomatic in its early stages but significantly increases the risk of stroke and heart failure. The silent nature of many arrhythmias underscores the clinical importance of continuous monitoring and early identification [3,4].

Hypertension plays a dual role, acting as both a cardiovascular disease and a major risk factor for other cardiovascular conditions. Chronic elevations in blood pressure lead to vascular remodeling, left ventricular hypertrophy, increased arterial stiffness, and microvascular damage. Over time, these changes contribute to the development of coronary heart disease, heart failure, and cerebrovascular complications. Target organ damage associated with hypertension often develops gradually, reinforcing the need for early diagnosis and intervention.

2.2 Clinical and Social Implications of Pathophysiology

Cardiovascular diseases (CVDs) are characterized by a prolonged latent phase, during which pathological changes progress without generating noticeable symptoms. This asymptomatic period represents a critical window for preventive intervention, but is often overlooked in traditional healthcare models, which rely primarily on symptomatic diagnosis. As a result, many patients are diagnosed only after irreversible organ damage or acute events such as myocardial infarction or stroke.

From a public health perspective, the pathophysiological characteristics of CVDs help explain their significant social burden. The chronic nature of these conditions, combined with their high prevalence and strong association with population aging, leads to increased healthcare utilization, reduced quality of life, and significant economic costs. Furthermore, the strong association between CVDs and modifiable lifestyle factors highlights the interplay between biological mechanisms and the social determinants of health [8,11]. Understanding the pathophysiology of cardiovascular disease provides the theoretical foundation for contemporary approaches to early detection and prevention. Subclinical electrical, structural, and functional changes precede overt clinical manifestations of disease and generate measurable signals in electrocardiographic recordings, imaging studies, laboratory biomarkers, and physiological monitoring data. These signals form the basis of modern risk stratification models and are particularly well-suited for analysis using artificial intelligence and machine learning techniques [2–5].

2.3 Importance for Early Detection and AI-Based Methods

The progressive, multifactorial, and data-rich nature of cardiovascular pathophysiology makes cardiovascular disease a paradigmatic example of conditions that can benefit from AI-assisted early detection. By integrating diverse data streams that reflect underlying biological processes, AI systems can identify patterns associated with early stages of disease, potentially enabling intervention before irreversible damage occurs. In this context, a clear understanding of the definitions of cardiovascular disease and pathophysiological mechanisms is essential not only for clinicians but also for the responsible development and implementation of AI-based diagnostic tools. Integrating technological innovations with biological and clinical knowledge ensures that AI systems address clinically relevant endpoints and support patient-centered, preventative care [7,9].

3. Literature review:

3.1 Artificial Inteligence in Early Detections of Heart Diseases

In recent years, artificial intelligence (AI) systems have rapidly evolved from experimental solutions to technologies with real clinical significance, capable of supporting the early detection of cardiovascular disease. This progress is driven by both the increasing availability of medical data and the increased computing power and development of advanced machine learning algorithms. In cardiology, AI enables the analysis of large, complex, and heterogeneous datasets, including electrocardiograms (ECGs), imaging data (echocardiography, computed tomography, magnetic resonance imaging), electronic health records (EHRs), as well as patient demographic, laboratory, and clinical information [2–4].

The use of machine learning (ML) and deep learning (DL) algorithms allows for the identification of subtle pathological patterns that may remain invisible in traditional clinical assessment. This applies particularly to early electrical and structural changes associated with heart failure, atrial fibrillation, or coronary artery disease, often before clinical symptoms appear [3–5]. In this context, AI can contribute to a shift in the healthcare paradigm from reactive treatment to preventive medicine, focused on early risk identification and intervention.

Another important area of AI application is the automation and standardization of imaging interpretation. AI-assisted tools can reduce interobserver variability, improve reproducibility, and shorten analysis time, which has not only clinical but also organizational and economic implications [5,10]. In healthcare systems struggling with a shortage of specialists, automating some diagnostic processes can play a significant role in optimizing resource utilization.

At the same time, it is emphasized that most currently implemented AI systems should function as clinical decision support tools, not autonomous diagnostic entities. Maintaining the physician's central role in the decision-making process is crucial both from the perspective of patient safety and ethical and legal responsibility [7].

The development of wearable technologies and consumer devices equipped with AI algorithms further expands the possibilities of early detection of heart disease beyond traditional healthcare environments. Continuous monitoring of physiological parameters such as heart rate and heart rate variability enables the identification of cardiovascular risk in asymptomatic individuals. This may support population-level screening strategies, but it also raises questions about overdiagnosis and the responsibility for interpreting data generated outside the healthcare system [4,7]., supporting preventive cardiology and population-based screening strategies [4,7].

3.2 Societal Impacts of AI-Assisted Cardiac Screenings

Implementing AI in cardiac screening has far-reaching social implications. One of the most frequently cited arguments in favor of these technologies is the potential to improve the availability of early diagnosis, especially in regions with limited access to specialized cardiac care. AI algorithms can support primary care providers in identifying high-risk patients, enabling earlier referral to specialist diagnostics [6,8].

From a public health perspective, AI can also contribute to more efficient use of healthcare system resources. Effective risk stratification can reduce the number of unnecessary tests and hospitalizations while simultaneously enabling the focus of resources on individuals at highest risk of developing heart disease. This approach is particularly important in the context of aging societies and the growing burden of chronic diseases.

At the same time, the potential societal benefits of AI are not evenly distributed. The effectiveness of algorithms depends largely on the quality and representativeness of training data, which often does not reflect the full diversity of the population in terms of gender, age, ethnicity, or socioeconomic status [3,11]. This could lead to a situation where AI works best for already privileged groups, while simultaneously exacerbating health inequalities.

An additional challenge remains the so-called digital divide, encompassing inequalities in access to technology, digital infrastructure, and healthcare literacy. Older people, those with lower levels of education, or those living in rural areas may have limited access to AI-based tools, limiting their potential benefits [11].

From the perspective of healthcare workflow, AI could also lead to a redefinition of the professional roles of doctors, nurses, and medical technicians. Automating some diagnostic tasks may increase work efficiency, but it also raises questions about competence, responsibility, and acceptance of these changes by medical personnel [8].

3.3 Ethical Challenges

The ethical aspects of implementing AI in the early diagnosis of heart disease are a key area of academic and public debate. One of the most frequently raised concerns is algorithmic bias, resulting from incomplete or unrepresentative datasets. This bias can lead to systematically poorer diagnostic results in specific patient groups, which contradicts the principle of equity in healthcare [3,9].

The lack of transparency and explainability of many AI models remains an equally significant challenge. "Black box" systems make it difficult to understand decision-making mechanisms, which can limit physicians' trust in algorithmic recommendations. The inability to explain AI decisions also poses a problem in the context of legal liability and the assessment of clinical errors [7,9].

Protecting data privacy and ensuring informed patient consent are other fundamental ethical issues. AI requires access to large amounts of sensitive health data, often collected continuously and long-term. Therefore, it is necessary to develop transparent data management principles that respect patient autonomy and minimize the risk of misuse [6,11].

3.4Trust, Doctor-Patient Relationship and AI

Trust is the foundation of an effective therapeutic relationship, and the integration of AI into clinical practice introduces new dynamics into the doctor-patient relationship. On the one hand, AI tools can foster trust if they are perceived to improve diagnostic accuracy and the safety of care [7,12]. On the other hand, patients may experience concerns about the increasing role of algorithms in decision-making, especially when they are not adequately informed about how these systems work. These concerns can range from loss of control over the treatment process to the potential "dehumanization" of healthcare [9,12].

Maintaining the physician as the central decision-maker and transparent communication with patients is therefore crucial. Explaining the role of AI, its limitations, and how it can be used in the diagnostic process promotes trust and collaborative therapeutic decision-making [12].

3.5Future Directions and Policy Implications

The future development of AI in the early detection of heart disease should be based on an integrated approach, encompassing technological development, legal regulations, and education. A key priority remains the creation of high-quality, diverse datasets that reduce the risk of algorithmic bias and increase the reliability of models [3,11].

Educational programs aimed at physicians, patients, and policymakers are also essential, aimed at improving competence in using AI. Without adequate training, even the most advanced technologies can be implemented ineffectively or unsafely [8].

At the health policy level, it is essential to develop a coherent regulatory framework that establishes standards for the validation, transparency, and monitoring of AI systems after their implementation. Interdisciplinary collaboration between clinicians, ethicists, lawyers, and patient representatives should be the foundation for the responsible development of these technologies [9,11].

3.6Conclusion

Artificial intelligence has significant potential to support early detection of heart disease and improve health outcomes at both the individual and population levels. However, its true societal value depends on its implementation, which must consider ethical considerations, equity of access, and maintaining trust in clinical relationships. AI is not a neutral tool, but a sociotechnical intervention requiring informed management, continuous assessment, and human-centered integration [6,7,9].

4. Materials and methods:

4.1 Study Character

This study is a narrative, interdisciplinary literature review with a conceptual and analytical focus. The aim of the study was to analyze the role of artificial intelligence in the early detection of heart disease from a social and ethical perspective. Due to the exploratory and interpretive nature of the subject matter, a qualitative research approach was employed, appropriate for analyses combining technological, medical, and social issues.

This article does not present the results of empirical research or clinical trials, but rather provides a synthetic analysis of existing scientific literature and theoretical positions relating to the implementation of AI technologies in healthcare.

4.2 Data Sources and Literature Search Strategy

The literature review was conducted using international scientific databases such as PubMed and Google Scholar. Strategic documents, guidelines, and position statements from organizations and scientific societies related to digital medicine, ethics, and public health were also considered. The search strategy included keyword combinations in English, including: "artificial intelligence," "machine learning," "early detection," "cardiovascular disease," "heart disease," "social impact," "ethical challenges," "healthcare inequality," "digital health," "trust," and "doctor–patient relationship."

The literature selection focused primarily on publications from recent years, particularly from 2024-2025, reflecting the dynamic development of AI technology, while also taking into account earlier works of fundamental importance to the discussed issues.

4.3 Inclusion and Exclusion Criteria

Publications meeting the following criteria were included in the analysis:

- articles published in peer-reviewed scientific journals or expert papers,
- papers on the application of artificial intelligence in cardiology, particularly in the context of early diagnosis, prevention, or screening,
- publications addressing social, ethical, legal, or systemic issues related to the use of AI in healthcare,
- availability of the full text in English. The following were excluded from the analysis:
- papers focused solely on the technical aspects of algorithms, without reference to the clinical or social context,
- publications not directly related to cardiovascular disease,
- non-peer-reviewed commentaries or reports without in-depth analysis.

4.4 Analytical Framework

The selected publications were subjected to a qualitative thematic analysis. The analysis identified key problem areas, including the technological potential of AI, accessibility and equity in healthcare, the risk of health inequalities, ethical challenges, personal data protection, and the impact of AI on trust and the doctor-patient relationship.

The analysis did not focus on comparing algorithm performance indicators, but rather on assessing the interaction of AI technologies with healthcare systems and social structures. This approach enabled critical reflection on the consequences of AI implementation beyond its technical effectiveness.

4.5 Rationale for Method Selection

The choice of a narrative literature review as the research method stemmed from the interdisciplinary nature of the topic under review and the journal's objectives. The social and ethical implications of technological innovations in healthcare require a qualitative approach, enabling the integration of knowledge from medicine, social sciences, and bioethics. This method allowed for a synthetic understanding of diverse research perspectives and the formulation of conclusions relevant to clinical practice, health policy, and public debate.

4.6 Methodological Limitations

This work has limitations typical of narrative literature reviews. The selection and interpretation of sources may involve a degree of subjectivity, and the lack of quantitative analysis prevents direct comparison of the effectiveness of individual AI-based solutions. However, these limitations are consistent with the exploratory and conceptual nature of the work and were minimized by considering a wide range of sources and research approaches.

5. List of abbreviations:

AI – Artificial Intelligence (Sztuczna inteligencja)
ML – Machine Learning (Uczenie maszynowe)
DL – Deep Learning (Głębokie uczenie)
ECG / EKG – Electrocardiogram (Elektrokardiogram)
EHR – Electronic Health Records (Elektroniczna dokumentacja medyczna)
CT – Computed Tomography (Tomografia komputerowa)
MRI – Magnetic Resonance Imaging (Rezonans magnetyczny)
GDPR – General Data Protection Regulation (Ogólne rozporządzenie o ochronie danych)
POZ – Primary Health Care (Podstawowa opieka zdrowotna)

Author's contribution:

Conceptualization and methodology – Paweł Słoma
Check - Paweł Słoma, Paulina Dybiak
Resources – Mateusz Bartoszek, Paweł Słoma
Investigation - Adrian Morawiec, Paweł Słoma
Form analysis - Maciej Zachara, Paweł Słoma
Writing - rough preparation - Patryk Harnicki, Paulina Dybiak, Paweł Słoma
Writing - review and editing - Erwin Grzegorzak, Paweł Słoma
Supervision - Oliwia Krawczyk, Paweł Słoma
Visualization - Rafał Pelczar, Paweł Słoma
Project administration - Mikołaj Grodzki, Jakub Minas, Paweł Słoma

All authors have read and agreed with the published version of the manuscript

Funding statement: The study did not receive special funding.

Conflict of interest statement: The authors declare that they have no conflict of interest.

REFERENCES

1. Wysocka, A., Potyra, M., Góral-Radziszewska, K., Waśkiewicz, K., & Gawińska-Drużba, E. (2025). *Life expectancy in Poland 2024* (Report). Główny Urząd Statystyczny.
2. Khan, M. S., Sreenivasan, J., Lateef, N., et al. (2024). *The role of artificial intelligence in heart failure diagnostics, risk prediction, and therapeutic strategies: A comprehensive review*. Cureus, 16(7), e87130. https://doi.org/10.7759/cureus.87130
3. Attia, Z. I., Friedman, P. A., Noseworthy, P. A., et al. (2017). *Age and sex estimation using artificial intelligence from standard 12-lead ECGs*. Journal of the American College of Cardiology, 69(21), 2657–2668. https://doi.org/10.1016/j.jacc.2017.03.571
4. Attia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., et al. (2018). *An artificial intelligence–enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm*. Journal of the American College of Cardiology, 71(19), 2112–2120. https://doi.org/10.1016/j.jacc.2018.03.521
5. Zhang, Y., Zhang, X., Liu, C., et al. (2022). *Artificial intelligence in cardiovascular medicine: Current status and future perspectives*. Reviews in Cardiovascular Medicine, 22(4), 121. https://doi.org/10.31083/j.rcm2204121
6. Patel, N., Shah, M., Desai, R., et al. (2024). *Ethical and social challenges of artificial intelligence in cardiovascular care*. Cureus, 16(9), e98378. https://doi.org/10.7759/cureus.98378
7. European Society of Cardiology. (2025). *Artificial intelligence in cardiovascular medicine: Policy and clinical implications*. European Heart Journal. Advance online publication. https://doi.org/10.1093/eurheartj/ehaf125
8. Johnson, K. W., Soto, J. T., Glicksberg, B. S., et al. (2025). *Artificial intelligence in preventive cardiology*. Heart Failure Clinics, 21(2), 115–128. https://doi.org/10.1016/j.hfc.2025.01.015
9. Topol, E. J., Rajpurkar, P., Lee, C. S., et al. (2025). *High-performance medicine: The convergence of human and artificial intelligence*. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-025-03517-w
10. Demir, M., Aydın, S., & Yılmaz, A. (2024). *Artificial intelligence applications in cardiovascular imaging*. Diagnostic and Interventional Radiology. Advance online publication. https://doi.org/10.4274/dir.2024.242854
11. Jones, D. S., Greene, J. A., & Kesselheim, A. S. (2024). *Ethical challenges of AI implementation in healthcare systems*. BMJ Open, 14(8), e089090. https://doi.org/10.1136/bmjopen-2024-089090
12. McDougall, R. J., Fogarty, J., & Miller, T. (2024). *Patient trust and artificial intelligence in healthcare decision-making*. Patient Education and Counseling, 120, 108619. https://doi.org/10.1016/j.pec.2024.108619